Login to Your Account



GSK Suspends Program

Chemocentryx Falls on Phase III Failure in Crohn's; Vercirnon Misses Endpoint

By Jennifer Boggs
Managing Editor

Monday, August 26, 2013
Chemocentryx Inc. will have to await word from partner Glaxosmithkline plc on the future of vercirnon after the CCR9 antagonist missed its endpoint in the first of four Phase III studies in moderate to severe Crohn's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription